SCA
JAZZ icon

Stonebridge Capital Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Stonebridge Capital Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1
Closed -$129 – 522
2023
Q3 		$129 Buy
+1
New +$133 ﹤0.01% 906
2020
Q3 		– Sell
-260
Closed -$29K – 446
2020
Q2 		$29K Hold
260
– – 0.01% 353
2020
Q1 		$26K Hold
260
– – 0.01% 351
2019
Q4 		$39K Hold
260
– – 0.01% 354
2019
Q3 		$33K Hold
260
– – 0.01% 377
2019
Q2 		$37K Buy
+260
New +$34.9K 0.01% 367

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Stonebridge Capital Advisors's JAZZ Position: Q4 2023 in Review

Stonebridge Capital Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2023, closing a stake of 1 share — an estimated $129 sold.

Stonebridge Capital Advisors first reported a position in JAZZ in Q2 2019 and held it in 6 quarters. The position peaked at $39K in Q4 2019. 500 funds tracked by Wall St. Rank hold JAZZ as of Q4 2023.

  • Stonebridge Capital Advisors reported no remaining Jazz Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Stonebridge Capital Advisors sold 1 Jazz Pharmaceuticals share in Q4 2023, an estimated $129.
  • Stonebridge Capital Advisors first reported a position in Jazz Pharmaceuticals in Q2 2019 and held it in 6 quarters.
  • Stonebridge Capital Advisors's Jazz Pharmaceuticals position peaked at $39K in Q4 2019.
  • 500 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2023.

Based on Stonebridge Capital Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.